Clinical trial
Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis
NCT06684184 is registered in ClinicalTrials.gov with Zhongming Qiu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis
- Lead sponsor
- Zhongming Qiu
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- November 30, 2024
- Completion date
- June 30, 2026
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
myasthaenia gravis